NASDAQ:EFTR

Effector Therapeutics Stock Predictions

etoro logo Buy EFTR
*Your capital is at risk
$0.0006
+0 (+0%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

EFTR Prediction Chart

EFTR Predictions History

Latest community submissions for EFTR.
Predictor Target Session Target Price Result Direction Accuracy Score
Jun 20, 2023 $0.97 -95.83% $0.775 X 75.21% 0
JS JS Pro
Jun 20, 2023 $0.93 -96.00% $0.775 X 80.26% 0
Jun 20, 2023 $0.790 -96.59% $0.775 V 98.06% 1
Jun 5, 2023 $1.12 -96.16% $1.01 V 88.88% 1
Jun 5, 2023 $1.14 -96.10% $1.01 V 87.11% 1
Jun 5, 2023 Bullish $1.01 X 0
Aug 8, 2022 Bullish $0.90 X 1
Aug 5, 2022 $2.41 -87.97% $0.82 X 0.00% 1
JS JS Pro
Sep 30, 2021 $15.02 -95.72% $14.05 X 93.10% 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for EFTR with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT EFFECTOR THERAPEUTICS, INC.
eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit euk...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE